Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit

Abstract Introduction Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by...

Full description

Bibliographic Details

Published in:	Infectious Diseases and Therapy
Main Authors:	Johnna Perdrizet, An Ta, Liping Huang, Warisa Wannaadisai, Aleksandar Ilic, Kyla Hayford, Ayman Sabra
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-02-01
Subjects:	Pneumococcal conjugate vaccine Pneumococcal disease PCV20 Policymakers Pediatric National immunization program
Online Access:	https://doi.org/10.1007/s40121-025-01108-3